Abbott Laboratories Reports Q3 2026 Growth Driven by Diagnostics and Medical Devices
Abbott Laboratories (ABT) reported strong third-quarter 2026 financial results, with total sales reaching $13.013 billion, a 14.5% increase driven by organic growth and the acquisition of Exact Sciences. Adjusted diluted EPS rose 9.2% to $1.42. Key performance drivers included a significant 46.7% reported surge in Diagnostics revenue and steady growth in Medical Devices, supported by the launch of the Volt PFA catheter. Strategically, Abbott announced plans to spin off its nutrition business into an independent, publicly traded entity by the end of 2027 to sharpen focus on innovation cycles. While the company saw broad success across segments like Diabetes Care and Established Pharmaceuticals, management noted headwinds including pricing pressures in international diabetes markets and a cybersecurity event that impacted cancer diagnostics momentum.
Topics: diagnostics earnings report EPS financial guidance medical devices revenue growth
Read the full article at Motley Fool
Part of the story Abbott Announces Nutrition Business Spin-off to Focus on High-Margin Medical Technologies (5 articles)